Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03939923 · ClinicalTrials.gov registry record · Phase 4
Role of Sugammadex as Reversal Agent in Patients Extubated Immediately After Isolated Coronary Artery Bypass Grafting Surgery
A Phase 4 study, sponsored by West Virginia University.
- Completed
- Registry status
- Phase 4
- Development phase
- 84
- Enrollment target
NCT03939923 is a Phase 4 study that has completed, run by West Virginia University. The registered enrollment target is 84 participants.
The verdict
NCT03939923, a Phase 4 study, has completed, sponsored by West Virginia University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 84 participants
- Enrollment target
Study Summary
The purpose of this study is to examine whether the use of Sugammadex will reduce time from reversal to extubation and improve other post extubation outcomes in Coronary artery bypass grafting patients. This study is a prospective, clinical interventional, randomized single blinded single-center design. The nurses in the cardiac intensive care unit will be blinded to treatment allocation (Group 1 or 2).
Interventions
- DRUG Rocuronium
- DRUG Sugammadex
- DRUG Neostigmine
- DRUG Glycopyrrolate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2019-05-01 |
| Est. Completion | 2021-07-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03939923
The ClinicalTrials.gov registry entry for NCT03939923 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is West Virginia University, which has 122 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Rocuronium is the first listed.
NCT03939923 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03939923 about?
NCT03939923 is a clinical study titled "Role of Sugammadex as Reversal Agent in Patients Extubated Immediately After Isolated Coronary Artery Bypass Grafting Surgery". The purpose of this study is to examine whether the use of Sugammadex will reduce time from reversal to extubation and improve other post extubation outcomes in Coronary artery bypass grafting patients. This study is a prospective, clinical interventional, randomized single blinded single-center des...
What is the current status of trial NCT03939923?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 84 participants. The study started on 2019-05-01. Estimated completion is 2021-07-30.
What interventions are being tested in trial NCT03939923?
The interventions under investigation include: Rocuronium (DRUG), Sugammadex (DRUG), Neostigmine (DRUG), Glycopyrrolate (DRUG).
Who is sponsoring clinical trial NCT03939923?
This trial is sponsored by West Virginia University, which has 122 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.